[go: up one dir, main page]

GT201000095A - Producto de dispersión sólida que contiene un compuesto a base de n-aril urea - Google Patents

Producto de dispersión sólida que contiene un compuesto a base de n-aril urea

Info

Publication number
GT201000095A
GT201000095A GT201000095A GT201000095A GT201000095A GT 201000095 A GT201000095 A GT 201000095A GT 201000095 A GT201000095 A GT 201000095A GT 201000095 A GT201000095 A GT 201000095A GT 201000095 A GT201000095 A GT 201000095A
Authority
GT
Guatemala
Prior art keywords
aril
urea
solid dispersion
based compound
product containing
Prior art date
Application number
GT201000095A
Other languages
English (en)
Inventor
Rudolf Schroeder
Tanja Heitermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000095A publication Critical patent/GT201000095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN PRODUCTO QUE COMPRENDE AL MENOS UN AGENTE FARMACÉUTICAMENTE ACTIVO A BASE DE N-ARIL UREA O UN AGENTE DE ESTRUCTURA RELACIONADA QUE ES OBTENIDO MEDIANTE A) LA PREPARACIÓN DE UNA MEZCLA LÍQUIDA QUE CONTIENE AL MENOS UN AGENTE ACTIVO, UN AGENTE FORMADOR DE MATRIZ ACEPTABLE PARA USO FARMACÉUTICO Y B) LA ELIMINACIÓN DEL O DE LOS SOLVENTES DE LA MEZCLA LÍQUIDA PARA OBTENER EL PRODUCTO DE DISPERSIÓN SÓLIDA.
GT201000095A 2007-10-19 2010-04-15 Producto de dispersión sólida que contiene un compuesto a base de n-aril urea GT201000095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
GT201000095A true GT201000095A (es) 2012-04-03

Family

ID=40089072

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000095A GT201000095A (es) 2007-10-19 2010-04-15 Producto de dispersión sólida que contiene un compuesto a base de n-aril urea

Country Status (23)

Country Link
US (1) US20090143423A1 (es)
EP (1) EP2197426A2 (es)
JP (1) JP2011500647A (es)
KR (1) KR20100090689A (es)
CN (1) CN101827585A (es)
AR (1) AR068916A1 (es)
AU (1) AU2008313620A1 (es)
BR (1) BRPI0818339A2 (es)
CA (1) CA2699335A1 (es)
CL (1) CL2008003092A1 (es)
CO (1) CO6270303A2 (es)
CR (1) CR11441A (es)
DO (1) DOP2010000114A (es)
EC (1) ECSP10010184A (es)
GT (1) GT201000095A (es)
MX (1) MX2010004292A (es)
PE (1) PE20091041A1 (es)
RU (1) RU2010119924A (es)
TW (1) TW200922549A (es)
UA (1) UA100866C2 (es)
UY (1) UY31406A1 (es)
WO (1) WO2009050289A2 (es)
ZA (1) ZA201002130B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045402A1 (en) * 2008-10-17 2010-04-22 Abbott Laboratories Trpv1 antagonists
US8604053B2 (en) * 2008-10-17 2013-12-10 Abbvie Inc. TRPV1 antagonists
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
CN102573755A (zh) * 2009-09-18 2012-07-11 巴斯夫欧洲公司 制备具有低水溶性的物质的制剂的方法
WO2012085236A1 (en) 2010-12-23 2012-06-28 Abbott Gmbh & Co. Kg Solid retard formulations based on solid dispersions
EP2663292B9 (en) * 2011-01-10 2017-11-08 Celgene Corporation Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
US20130172239A1 (en) * 2011-12-29 2013-07-04 Abbvie Inc. Solid compositions
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112014011938B1 (pt) 2013-01-31 2021-03-16 Gilead Pharmasset Llc composição farmacêutica na forma de um comprimido com uma combinação de dose fixa de dois compostos antivirais, forma de dosagem farmacêutica compreendendo a referida composição e uso da referida composição
AU2014233705C1 (en) 2013-03-15 2019-10-10 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
EP3145504B1 (en) 2014-05-20 2023-07-26 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
EP3307246A1 (en) 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US12186314B2 (en) * 2015-12-22 2025-01-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
SG11202104208RA (en) * 2018-10-30 2021-05-28 Peloton Therapeutics Inc Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
EP4410989A3 (en) 2019-08-23 2024-12-11 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US6001860A (en) * 1992-05-28 1999-12-14 Pfizer Inc. N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT)
CA2302735A1 (en) * 1998-07-14 2000-01-27 Em Industries, Inc. Microdisperse drug delivery systems
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
RU2373923C2 (ru) * 2004-06-08 2009-11-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции
ES2306216T3 (es) * 2004-08-27 2008-11-01 Bayer Pharmaceuticals Corporation Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
EP1877042A4 (en) * 2005-04-18 2011-03-02 Rubicon Res Private Ltd BIOLOGICALLY IMPROVED COMPOSITIONS
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US7745448B2 (en) * 2005-12-28 2010-06-29 Abbott Laboratories Inc. Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate
BRPI0707584A2 (pt) * 2006-02-09 2011-05-10 Merck & Co Inc composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica

Also Published As

Publication number Publication date
AR068916A1 (es) 2009-12-16
TW200922549A (en) 2009-06-01
CN101827585A (zh) 2010-09-08
EP2197426A2 (en) 2010-06-23
CO6270303A2 (es) 2011-04-20
KR20100090689A (ko) 2010-08-16
UY31406A1 (es) 2009-05-29
UA100866C2 (ru) 2013-02-11
CR11441A (es) 2010-10-25
RU2010119924A (ru) 2011-11-27
JP2011500647A (ja) 2011-01-06
ECSP10010184A (es) 2010-06-29
BRPI0818339A2 (pt) 2015-04-22
CA2699335A1 (en) 2009-04-23
WO2009050289A3 (en) 2010-03-25
AU2008313620A1 (en) 2009-04-23
PE20091041A1 (es) 2009-08-22
CL2008003092A1 (es) 2009-11-27
MX2010004292A (es) 2010-08-02
DOP2010000114A (es) 2010-05-15
WO2009050289A2 (en) 2009-04-23
ZA201002130B (en) 2011-11-30
US20090143423A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
PA8800101A1 (es) Producto de dispersion sólida que contiene un compuesto a base de n-aril urea
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
AR051969A1 (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
WO2010041141A3 (en) Oil-based foamable carriers and formulations
UY30107A1 (es) Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
BR112015018087A8 (pt) composto, composição farmacêutica e uso
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
ES2484721T3 (es) Mezcla fluidizante para composición hidráulica
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
PE20090607A1 (es) Formulacion farmaceutica de dispersion liposomal en polvo seco
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
CO6351722A2 (es) Derivados heterociclicos de la urea y sus metodos de empleo
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR060869A1 (es) Composicion farmaceutica solida de gabapentina
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
CL2007002103A1 (es) Uso de pramipexol y un analgesico derivado del acido gamma aminobutirico para tratar el dolor; y composicion farmaceutica que los comprende.